AbbVie receives FDA approval for subcutaneous induction regimen of SKYRIZI in Crohn's disease

AbbVie received FDA approval for its subcutaneous induction regimen for SKYRIZI to treat moderately to severely active Crohn's disease.

Detected & updated continuously · Source: Nebula